Psyence Biomedical Ltd. (PBM) News
Track canonical SquawkNews coverage tagged to PBM, Psyence Biomedical Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Psyence Biomedical Ltd. (PBM) Secures Exclusive U.S. Ibogaine Licence via Binding Term Sheet
Psyence Biomedical said its Texas unit signed a binding term sheet with PsyLabs for exclusive U.S. licence, supply and distribution of pharmaceutical-grade ibogaine. Milestones total up to ~$1.3M for the first candidate;
NEWS | Sep 28, 2026, 11:09 AM UTC
L
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreementNEW Y
NEWS | Sep 28, 2026, 11:08 AM UTC
L
Psyence Biomedical Ltd. (PBM) To Invest Up To $5M In PsyLabs, Execute ~$9M Share Exchange
Psyence Biomedical Ltd. agreed to invest up to $5M in PsyLabs and a reciprocal ~$9M share-for-share exchange to support a planned U.S. ibogaine program in Texas, subject to approvals and conditions.Material DetailsContex
NEWS | Sep 23, 2026, 11:03 AM UTC
L
Psyence BioMed Announces Strategic Ibogaine Investment
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchangeHighlightsNEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. NASDAQ:PBM
NEWS | Sep 23, 2026, 11:03 AM UTC
L
PBM - Psyence BioMed Announces Strategic Ibogaine Investment
PBM - Psyence BioMed Announces Strategic Ibogaine Investment
NEWS | Sep 23, 2026, 11:00 AM UTC
L
As Trump backs psychedelics research, FDA weighs safety and access standards
By Nancy LapidThe U.S. FDA heard calls for clear safety and access standards for psychedelic therapies at a public meeting, the latest step in the Trump administration's push to speed development of treatments such as ib
REGULATION | Sep 15, 2026, 03:16 PM UTC
L
Aurwest Resources completes Phase 1 exploration at Weaver Lake
Aurwest Resources completed its Phase 1 exploration program at the Weaver Lake gold project.
COMMODITIES | Aug 27, 2026, 12:01 PM UTC
L
Psyence BioMed welcomes U.S. action to speed ibogaine development
Psyence BioMed says it welcomes the U.S. administration’s latest action to accelerate ibogaine development.
REGULATION | Aug 18, 2026, 09:23 PM UTC